ATLANTA, GA – – (Globe Newswire – April 27, 2026) – – A shareholder class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Regencell’s business, operations, and compliance policies, including allegations that: (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; and (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm.

If you purchased Regencell shares between October 28, 2024 and October 31, 2025, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/regencell-bioscience-holdings/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is June 23, 2026.